Propofol Infusion Syndrome in Refractory Status Epilepticus: A Case Report and Topical Review

Table 1

Clinical presentation and investigations.

	Survived	Died
Sex (female/male)	3/4	2/11
Age (years), mean (range)	21,1 (9 months–55)	36,5 (7–64)
Children ()	2	2
Type of epilepsy, (%)
NCSE	—	4 (28,6)
SPSE	1 (14,3)	4 (28,6)
CPSE	—	2 (14,3)
GTCSE	4 (57,1)	2 (14,3)
Unknown	2 (28,6)	2 (14,3)
Duration of propofol infusion, hours (±SD)	54,4 (±20,2)	72,2 (±22,2)
Propofol doses (mg/kg/hr), mean (±SD)	8,8 (±4,4)	9,8 (±3,8)
ECG changes
RBBB	2 (28,6)	3 (21,4)
Brugada	1 (14,3)	1 (7,14)
Wide QRS	2 (28,6)	4 (28,6)
Prolonged QTc	2 (28,6)	3 (21,4)
Sinus bradycardia	2 (28,6)	5 (35,7)
Torsade de Pointes	1 (14,3)	1 (7,14)
Asystole		1 (7,14)
PEA		1 (7,14)
Rhabdomyolysis, (%)	1 (14,3)	8 (57,1)
Lactic acidosis, (%)	5 (71,4)	8 (57,1)
Renal failure, (%)	4 (57,1)	4 (28,6)
Triglyceridemia, (%)	3 (42,9)	4 (28,6)
Elevated liver enzymes, (%)	3 (42,9)	2 (14,3)

NCSE: nonconvulsive status epilepticus; SPSE: simple partial status epilepticus; CPSE: complex partial status epilepticus; GTCSE: general tonic-clonic status epilepticus; RBBB: right bundle branch block; PEA: pulseless electrical activity.